KE / Domain	AOP entity (KE/KER)	Input (manipulation / sample)	Method / Assay (SOP notes)	Output / Measurement	Interpretation / Context fields to capture	Exemplar peer-reviewed manuscripts	Protocol / SOP notes (attach)	S&T considerations (ontology / mapping)
EGFR activation → Mucin production (increased)	MIE: EGFR Activation (Event 2); KER: EGFR activation → Goblet cell hyperplasia → Mucin production ↑; part of oxidative stress AOP network	Human airway epithelial cells; rodent tracheal epithelial cells; in vitro and in vivo models; stimulation with EGF, TGF-α, or EGFR agonists	EGFR ligand stimulation assays. Western blot for EGFR phosphorylation (pEGFR). Mucin gene expression by RT-PCR or Northern blot (MUC5AC, MUC5B). Mucin protein quantification by ELISA or immunohistochemistry. EGFR inhibitor studies to confirm pathway involvement.	EGFR phosphorylation levels (fold change); Mucin gene expression (MUC5AC, MUC5B mRNA levels); Mucin protein levels; Goblet cell counts; Dose-response and time-course data	Cell type and species; culture conditions; EGF or TGF-α concentration; stimulation duration; EGFR inhibitor type and concentration; detection antibodies; normalization method; passage number; replicate number; statistical analysis	Takeyama K, Dabbagh K, Lee HM, Agustí C, Lausier JA, Ueki IF, Grattan KM, Nadel JA. (1999). Epidermal growth factor system regulates mucin production in airways. Proc Natl Acad Sci U S A. 96(6):3081-6.	Include EGF/TGF-α preparation and dosing, cell stimulation protocol, Western blot conditions, RT-PCR primers, mucin quantification method, controls (vehicle, EGFR inhibitor), time-course design	Biolink: MeasurementProcess; OBI: Western blot assay, RT-PCR assay; Mapping: MIE EGFR activation, KER EGFR → mucin; CHEBI: EGF, TGF-α, EGFR inhibitors; Pathway: EGFR signaling
EGFR activation and airway inflammatory response	MIE: EGFR Activation (Event 2); relationship to inflammatory cytokine production and mucin secretion	Human bronchial epithelial cells; animal models of airway disease; EGFR agonist or oxidative stress stimulation	EGFR activation assessment by phospho-EGFR Western blot or immunofluorescence. Downstream signaling pathway analysis (ERK, AKT phosphorylation). Inflammatory cytokine measurement by ELISA or multiplex assay (IL-8, IL-6). Mucin production assays. EGFR kinase inhibitor validation.	pEGFR levels; Downstream kinase activation (pERK, pAKT); Cytokine levels (IL-6, IL-8, TNF-α); Mucin gene/protein expression; EGFR inhibitor effects	Cell line or primary cells; passage number; stimulation conditions (oxidant, cytokine, EGFR ligand); concentration and duration; inhibitor type and dose; assay platforms; antibody specifics; normalization approach; time-course sampling	Huang et al. (2017). [EGFR signaling in airway inflammation].	Document stimulation protocol, Western blot/immunofluorescence procedures, ELISA protocols, inhibitor validation, signal quantification methods, quality controls	Biolink: MeasurementProcess; OBI: Western blot, ELISA; Mapping: MIE EGFR activation, downstream inflammatory signaling; Pathway: EGFR-MAPK-cytokine axis
Oxidative stress → EGFR activation	KER: Oxidative stress → EGFR activation; MIE: Oxidative Stress (Event 1) → MIE: EGFR Activation (Event 2)	Human bronchial epithelial cells; exposure to oxidative stressors (H₂O₂, diesel exhaust particles, cigarette smoke extract)	Oxidant exposure followed by EGFR phosphorylation assessment. Western blot for pEGFR (Tyr1068, Tyr1173). Time-course analysis of EGFR activation. Antioxidant pre-treatment to confirm oxidative mechanism. Reactive oxygen species (ROS) measurement by fluorescent probes (DCFDA).	ROS levels (fluorescence intensity); EGFR phosphorylation (pEGFR at specific tyrosine residues); Time to peak activation; Antioxidant inhibition of EGFR activation; Downstream signaling activation	Cell type; oxidant type and concentration; exposure duration; antioxidant type and dose; ROS probe type; Western blot antibodies and conditions; time-course intervals; replicate number; vehicle controls	Ovrevik J, Refsnes M, Låg M, Holme JA, Schwarze PE. (2011). Activation of proinflammatory responses in cells of the airway mucosa by particulate matter: oxidant- and non-oxidant-mediated triggering mechanisms. Biomolecules. 1(1):31-50.	Include oxidant preparation and dosing, ROS measurement protocol, Western blot for pEGFR, antioxidant pre-treatment protocol, time-course design, quantification of blots	Biolink: MeasurementProcess; OBI: Western blot, fluorescence assay; Mapping: KER oxidative stress → EGFR; CHEBI: H₂O₂, antioxidants; Mechanistic link in AOP network
EGFR signaling in airway remodeling	MIE: EGFR Activation (Event 2); role in goblet cell metaplasia and mucus hypersecretion	Primary human airway epithelial cells at ALI; in vivo mouse models; EGFR ligand stimulation or environmental exposures	Multi-endpoint assessment of EGFR pathway. Phospho-EGFR by Western blot or phospho-flow cytometry. Goblet cell quantification by histology (Alcian Blue/PAS staining) or Muc5AC immunostaining. Gene expression profiling for EGFR pathway components and mucin genes (qRT-PCR, RNA-seq).	pEGFR levels; Goblet cell numbers and percentage; MUC5AC expression (mRNA and protein); EGFR ligand expression (EGF, TGF-α, AREG); Pathway target genes	Cell donor characteristics; culture model (ALI conditions, days at ALI); stimulation type and dose; in vivo exposure conditions; histology protocols; qRT-PCR primers and normalization genes; sequencing platform; image analysis for cell counting; replicate number	Wang et al. (2024). [EGFR signaling in airway disease].	Include cell culture/ALI differentiation protocol, stimulation conditions, Western blot procedures, histology and staining protocols, immunofluorescence imaging, qRT-PCR or RNA-seq methods, image quantification workflow	Biolink: MeasurementProcess; OBI: Western blot, histology, gene expression profiling; Mapping: MIE EGFR, KE goblet cell hyperplasia, KE mucin production; Multi-scale integration
EGFR pathway biomarkers in clinical samples	MIE: EGFR Activation (Event 2); clinical translation and biomarker development	Human clinical samples (sputum, BALF, tissue biopsies); patient cohorts with respiratory disease	EGFR and downstream signaling assessment in clinical specimens. Immunohistochemistry for pEGFR in tissue. ELISA for soluble EGFR ligands in BALF/sputum. Multiplex assays for pathway components. Correlation with clinical outcomes (lung function, exacerbations).	pEGFR expression in tissue; Soluble EGFR ligand levels (sEGF, sTGF-α); Pathway biomarker signatures; Correlation with disease severity or outcomes	Patient demographics and clinical characteristics; disease diagnosis; sample type and collection method; processing and storage conditions; assay platforms; antibody specifications; normalization method; statistical analysis for biomarker-outcome correlations; quality control	Misiukiewicz-Stepien et al. (2025). [EGFR pathway in clinical respiratory disease].	Document clinical sample collection and processing, immunohistochemistry protocol, ELISA procedures, biomarker validation approach, statistical analysis plan, quality assurance measures	Biolink: MeasurementProcess; OBI: immunohistochemistry, ELISA; Mapping: MIE EGFR activation in clinical context; Clinical biomarker; Translation to human disease
EGFR in airway epithelial injury and repair	MIE: EGFR Activation (Event 2); role in epithelial regeneration and pathological remodeling	Primary airway epithelial cells; wound healing assays; in vitro injury models; EGFR ligand stimulation	Epithelial wound healing and EGFR activation. Scratch assay or electric cell-substrate impedance sensing (ECIS) for migration/repair. EGFR phosphorylation time-course during repair. Cell proliferation assays (BrdU, Ki67). EGFR inhibitor effects on repair kinetics.	Wound closure rate (%/hour); Cell migration velocity; EGFR activation kinetics during repair; Proliferation markers; EGFR inhibitor effects on repair	Cell type and passage; wounding method; EGFR ligand type and concentration; inhibitor type and dose; imaging interval; repair quantification method; proliferation assay specifics; replicate number; environmental conditions	Paplinska-Goryca et al. (2025). [EGFR in airway epithelial repair].	Include wounding protocol, imaging and quantification of repair, EGFR activation assessment during time-course, proliferation assay protocol, EGFR inhibitor studies, controls	Biolink: MeasurementProcess; OBI: cell migration assay, proliferation assay; Mapping: MIE EGFR in context of injury/repair; Dual role of EGFR in normal vs pathological remodeling
